37 results on '"Nguyen-Khac, Eric"'
Search Results
2. International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendations
- Author
-
Cadranel, Jean-François David, Ollivier-Hourmand, Isabelle, Cadranel, Jacques, Thevenot, Thierry, Zougmore, Honoré, Nguyen-Khac, Eric, Bureau, Christophe, Allaire, Manon, Nousbaum, Jean-Baptiste, Loustaud-Ratti, Véronique, Causse, Xavier, Sogni, Philippe, Hanslik, Bertrand, Bourliere, Marc, Peron, Jean-Marie, Ganne-Carrie, Nathalie, Dao, Thong, Thabut, Dominique, Maitre, Bernard., Debzi, Nabil, Smadhi, Ryad, Sombie, Roger, Kpossou, Raimi, Nouel, Olivier, Bissonnette, Julien, Ruiz, Isaac, Medmoun, Mourad, Dastis, Sergio Negrin, Deltenre, Pierre, Artru, Florent, Raherison, Chantal, Elkrief, Laure, and Lemagoarou, Tristan
- Published
- 2023
- Full Text
- View/download PDF
3. Shotgun Metagenomics Reveals Bacteroides stercoris as a Fecal Biomarker Depleted in Late-stage Hepatocellular Carcinoma
- Author
-
Esparteiro, Damien, Fouquet, Grégory, Courtois, Anoïsia, Naassila, Mickaël, Nguyen-Khac, Eric, and Marcq, Ingrid
- Published
- 2024
- Full Text
- View/download PDF
4. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
- Author
-
Nahon, Pierre, Asselah, Tarik, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Pageaux, Georges-Philippe, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Decaensi, Thomas, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Chazouillères, Olivier, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, d’Alteroche, Louis, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen-Khac, Eric, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Cheraud-Carpentier, Marjorie, Hubert, Isabelle, Benhida, Jaouad, Lannes, Adrien, Lunel, Françoise, Oberti, Frédéric, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Wilson, Amy, Shili, Sarah, Chermak, Faiza, Ansaldi, Christelle, Ben Amara, Nisserine, Chouquet, Laëtitia, De Luca, Emilie, Oules, Valérie, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, De Dieuleveult, Barbara, Labarriere, Damien, Poter, Pascal, Si Ahmed, Si Nafa, Grando-Lemaire, Véronique, Bourcier, Valérie, Brulé, Séverine, Stalhberger, Thomas, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F., Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphanie, Ripault, Marie Pierre, Bureau, Christophe, Peron, Jean Marie, Robic, Marie Angèle, Tarallo, Léa, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, Montialoux, Hélène, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Duclos Vallée, Jean-Charles, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldine, Muti, Léon, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièle, Saillard, Eric, Lafrance, Marie-Josée, Cacoub, Patrice, Carrat, Fabrice, Carrieri, Patrizia, Delarocque-Astagneau, Elisabeth, De Ledinghen, Victor, Dorival, Céline, Dubuisson, Jean, Housset, Chantal, Larrey, Dominique, Marcellin, Patrick, Pawlotsky, Jean-Michel, Petrov-Sanchez, Ventzislava, Vaux, Sophie, Wittkop, Linda, Yazdanpanah, Yazdan, Zucman-Rossi, Jessica, Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Moreno, Christophe, Moirand, Romain, Carbonell, Nicolas, Duclos-Vallée, Jean-Charles, de Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Perlemuter, Gabriel, Amiot, Xavier, Chevret, Sylvie, Najean, Marie, Layese, Richard, Zarca, Kevin, Segar, Laeticia Blampain, Cagnot, Carole, N’Kontchou, Gisèle, Ronot, Maxime, Audureau, Etienne, and Durand-Zaleski, Isabelle
- Published
- 2022
- Full Text
- View/download PDF
5. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
- Author
-
Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Archambeaud, Isabelle, d’Alteroche, Louis, Oberti, Frédéric, Roulot, Dominique, Moreno, Christophe, Louvet, Alexandre, Dao, Thông, Moirand, Romain, Goria, Odile, Nguyen-Khac, Eric, Carbonell, Nicolas, Duclos-Vallée, Jean-Charles, Pol, Stanislas, de Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Péron, Jean-Marie, Tran, Albert, Perlemuter, Gabriel, Amiot, Xavier, Zarski, Jean-Pierre, Chevret, Sylvie, Nahon, Pierre, Asselah, Tarik, Guyader, Dominique, Fontaine, Hélène, Pageaux, Georges-Philippe, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Bronowicki, Jean-Pierre, Decaens, Thomas, Riachi, Ghassan, Calès, Paul, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Chazouillères, Olivier, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Wartelle, Claire, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, N’Kontchou, Gisèle, Layese, Richard, and Audureau, Etienne
- Published
- 2021
- Full Text
- View/download PDF
6. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis
- Author
-
Yzet, Clara, Diouf, Momar, Singh, Siddarth, Brazier, Franck, Turpin, Justine, Nguyen-Khac, Eric, Meynier, Jonathan, and Fumery, Mathurin
- Published
- 2021
- Full Text
- View/download PDF
7. Generalized pruritus in dysmetabolic hyperferritinemia treated by phlebotomy
- Author
-
Brigant, Fanny, Hautefeuille, Vincent, Dadban, Ali, Lok, Catherine, Nguyen-Khac, Eric, and Chaby, Guillaume
- Subjects
pruritus ,dysmetabolic ,hyperferritinemia ,phlebotomy ,metabolic syndrome ,hepatic iron overload - Abstract
This paper describes a case of pruritus caused by dysmetabolic hyperferritinemia treated by multiple phlebotomies.A 63-year-old man was followed for generalized pruritus, which was resistant to the usual treatments. He presented with metabolic syndrome. Physical examination showed only excoriations and lichenification on the skin. The serum ferritin was high at 1043 ng/ml, with transferrin saturation at 67%. The other biological investigations and genetic tests for hemochromatosis were negative.In spite of the dietary measures, the ferritin level was still high (853ng/ml). Magnetic resonance imaging confirmed hepatic iron overload.The association of hyperferritinemia, hepatic iron overload, and metabolic syndrome led to the diagnosis of dysmetabolic hyperferritinemia.Phlebotomies are an unusual treatment, but because the pruritus and hyperferritinemia were still present, phlebotomy wasinitiated. After 19 months, the patient reported improvement of his pruritus and normalization of ferritin levels.
- Published
- 2015
8. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
- Author
-
Nahon, Pierre, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Zarski, Jean-Pierre, Leroy, Vincent, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Serfaty, Lawrence, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen-Khac, Eric, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, Layese, Richard, Bourcier, Valérie, Cagnot, Carole, Zucman, David, Sutton, Angela, Roudot-Thoraval, Françoise, and Audureau, Etienne
- Published
- 2018
- Full Text
- View/download PDF
9. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study
- Author
-
Nahon, Pierre, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Zarski, Jean-Pierre, Leroy, Vincent, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Serfaty, Lawrence, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Capron, Dominique, Thiefin, Gérard, Hillaire, Sophie, Di Martino, Vincent, Costentin, Charlotte E., Layese, Richard, Bourcier, Valérie, Cagnot, Carole, Nguyen-khac, Eric, Bernard-Chabert, Brigitte, Zucman, David, Sutton, Angela, Letouzé, Eric, Imbeaud, Sandrine, Zucman-Rossi, Jessica, Audureau, Etienne, and Roudot-Thoraval, Françoise
- Published
- 2018
- Full Text
- View/download PDF
10. Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort
- Author
-
Loreau, Julien, Duricova, Dana, Gower-Rousseau, Corinne, Savoye, Guillaume, Ganry, Olivier, Ben Khadhra, Hajer, Sarter, Hélène, Yzet, Clara, Le Mouel, Jean-Philippe, Kohut, Mathieu, Brazier, Franck, Chatelain, Denis, Nguyen-Khac, Eric, Dupas, Jean-Louis, and Fumery, Mathurin
- Published
- 2019
- Full Text
- View/download PDF
11. Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation
- Author
-
Minoux, Kate, primary, Lassailly, Guillaume, additional, Ningarhari, Massih, additional, Lubret, Henri, additional, El Amrani, Medhi, additional, Canva, Valérie, additional, Truant, Stéphanie, additional, Mathurin, Philippe, additional, Louvet, Alexandre, additional, Lebuffe, Gilles, additional, Goria, Odile, additional, Nguyen-Khac, Eric, additional, Boleslawski, Emmanuel, additional, and Dharancy, Sebastien, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Alfapump®implantable device in management of refractory ascites: An update
- Author
-
Weil-Verhoeven, Delphine, primary, Di Martino, Vincent, additional, Stirnimann, Guido, additional, Cervoni, Jean Paul, additional, Nguyen-Khac, Eric, additional, and Thévenot, Thierry, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Alfapump® implantable device in management of refractory ascites: An update
- Author
-
Weil-Verhoeven, Delphine, Di Martino, Vincent, Stirnimann, Guido, Cervoni, Jean Paul, Nguyen-Khac, Eric, and Thévenot, Thierry
- Subjects
Hepatology ,610 Medicine & health - Abstract
Refractory ascites (RA) is a frequent and life-threatening complication of cirrhosis. In selected patients with RA, transjugular intrahepatic portosystemic shunt (TIPS) placement and liver transplantation (LT) are currently considered the best therapeutic alternatives to repeated large volume paracentesis. In patients with a contraindication to TIPS or LT, the alfapump® system (Sequana Medical, Ghent, Belgium) has been developed to reduce the need for iterative paracentesis, and consequently to improve the quality of life and nutritional status. We report here recent data on technical progress made since the first implantation, the efficacy and tolerance of the device, the position of the pump in the therapeutic arsenal for refractory ascites, and the grey areas that remain to be clarified regarding the optimal selection of patients who are potential candidates for this treatment.
- Published
- 2022
- Full Text
- View/download PDF
14. Low Levels of Hepatitis C Virus (HCV) Neutralizing Antibodies in Patients Coinfected with HCV and Human Immunodeficiency Virus
- Author
-
Castelain, Sandrine, Schnuriger, Aurélie, François, Catherine, Nguyen-Khac, Eric, Fournier, Carole, Schmit, Jean-Luc, Capron, Dominique, Dubuisson, Jean, Wychowski, Czeslaw, Thibault, Vincent, and Duverlie, Gilles
- Published
- 2008
- Full Text
- View/download PDF
15. Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition
- Author
-
Fouquet, Grégory, primary, Marié, Constance, additional, Collet, Louison, additional, Vilpoux, Catherine, additional, Ouled-Haddou, Hakim, additional, Nguyen-Khac, Eric, additional, Bayry, Jagadeesh, additional, Naassila, Mickaël, additional, Marcq, Ingrid, additional, and Bouhlal, Hicham, additional
- Published
- 2022
- Full Text
- View/download PDF
16. Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus
- Author
-
Brayette, Anaïs, primary, Essig, Marie, additional, Carrier, Paul, additional, Debette-Gratien, Marilyne, additional, Labrunie, Anaïs, additional, Alain, Sophie, additional, Maynard, Marianne, additional, Ganne-Carrié, Nathalie, additional, Nguyen-Khac, Eric, additional, Pinet, Pauline, additional, De Ledinghen, Victor, additional, Renou, Christophe, additional, Mathurin, Philippe, additional, Vanlemmens, Claire, additional, Di Martino, Vincent, additional, Gervais, Anne, additional, Foucher, Juliette, additional, Isabelle, Fouchard-Hubert, additional, Vergniol, Julien, additional, Hourmand-Ollivier, Isabelle, additional, Cohen, Daniel, additional, Duval, Xavier, additional, Poynard, Thierry, additional, Bardou, Marc, additional, Abergel, Armand, additional, Dao, Manh-Thong, additional, Thévenot, Thierry, additional, Hiriart, Jean-Baptiste, additional, Canva, Valérie, additional, Lassailly, Guillaume, additional, Aurières, Christine, additional, Boyer, Nathalie, additional, Thabut, Dominique, additional, Bernard, Pierre-Henri, additional, Schnee, Matthieu, additional, Larrey, Dominique, additional, Hanslik, Bertrand, additional, Hommel, Séverine, additional, Jacques, Jérémie, additional, and Loustaud-Ratti, Véronique, additional
- Published
- 2020
- Full Text
- View/download PDF
17. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
- Author
-
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, RELIVE Investigators, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, and RELIVE Investigators
- Abstract
BACKGROUND: Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed. METHODS: We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Patients with hepatocellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly assigned to receive 30 mg/m2 doxorubicin-loaded nanoparticles (30 mg/m2 group), 20 mg/m2 doxorubicin-loaded nanoparticles (20 mg/m2 group), or standard care using a computer-generated randomisation list prepared by the funder and stratified by geographic region. Patients in the experimental groups received perfusion of the drug every 4 weeks and those in the control group received any systemic anticancer therapy (except sorafenib) as per investigator decision. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the population of patients who received at least one dose of their assigned treatment. This trial is registered with ClinicalTrials.gov, number NCT01655693. FINDINGS: Between June 15, 2012, and Jan 27, 2017, 541 patients were screened, of whom 144 were excluded and 397 were randomly assigned to one of the groups (133 to the 30 mg/m2 group; 130 to the 20 mg/m2 group; and 134 to the control group). Median follow-up was 22·7 months (IQR 11·2-34·9). After pooling the doxorubicin groups for the efficacy analysis, median overall survival was 9·1 months (95% CI 8·1-10·4) in the pooled doxorubicin-loaded nanoparticles group and 9·0 months (7·1-11·8) in the control group (HR 1·00 [95% CI 0·78-1·28], two-sided p=0·99). 227 (94%) of 242 patients who received doxorubicin-loaded nanoparticles and 100 (75%) of 134 patients in the control group had at least one treatment-emergent adverse event. The most common drug-related grade 3 or 4 tr
- Published
- 2019
18. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis
- Author
-
Nguyen-Khac, Eric, Thiele, Maja, Voican, Cosmin, Nahon, Pierre, Moreno, Christophe, Boursier, Jérôme, Mueller, Sebastian, De Ledinghen, Victor, Starkel, Peter, Gyune Kim, Sang, Fernandez Y Viesca, Michael, Madsen, Bjorn, Naveau, Sylvie, Krag, Aleksander, Perlemuter, Gabriel, Ziol, Marianne, Chatelain, Denis, Diouf, Momar, Nguyen-Khac, Eric, Thiele, Maja, Voican, Cosmin, Nahon, Pierre, Moreno, Christophe, Boursier, Jérôme, Mueller, Sebastian, De Ledinghen, Victor, Starkel, Peter, Gyune Kim, Sang, Fernandez Y Viesca, Michael, Madsen, Bjorn, Naveau, Sylvie, Krag, Aleksander, Perlemuter, Gabriel, Ziol, Marianne, Chatelain, Denis, and Diouf, Momar
- Abstract
Background: The value of transient elastography for the non-invasive diagnosis of alcohol-related liver fibrosis is subject to debate. We did an individual patient data (IPD) meta-analysis to determine specific diagnostic cutoff values for liver stiffness in alcohol-related fibrosis, and to assess the effect of aminotransferase concentrations, bilirubin concentrations, and presence of asymptomatic and non-severe alcoholic hepatitis on liver stiffness. Methods: We searched for studies that included patients with alcohol-related liver disease, liver biopsy, and transient elastography, and with a statistical method for determining the diagnostic cutoffs for alcohol-induced liver fibrosis on the basis of the FibroScan results, in PubMed between Jan 1, 2000, and Sept 30, 2017. Native data bases were obtained from corresponding authors in an Excel form. Pooled diagnostic cutoffs for the various fibrosis stages were determined in a two-stage, random-effects meta-analysis. The effects of aspartate aminotransferase (AST) concentrations, bilirubin concentrations, and histological features of asymptomatic and non-severe alcoholic hepatitis on liver stiffness cutoff were assessed in one-stage, random-effects meta-analysis. Findings: Of 188 studies assessed, ten studies comprising 1026 patients were included in the meta-analysis, yielded liver stiffness cutoffs of 7·0 kPa (area under the receiver operating characteristic curve 0·83 [SE 0·02; 95% CI 0·79–0·87]) for F≥1 fibrosis, 9·0 kPa (0·86 [0·02; 0·82–0·90]) for F≥2, 12·1 kPa (0·90 [0·02; 0·86–0·94]) for F≥3, and 18·6 kPa (0·91 [0·04; 0·83–0·99]) for F=4. AST and bilirubin concentrations had a significant effect on liver stiffness, with higher concentrations associated with higher liver stiffness values (p<0·0001), and with significantly higher cutoff values for diagnosis of all fibrosis stages but F≥1. The presence of histological features of asymptomatic and non-severe alcoholic hepatitis was associated with increased liver, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2018
19. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis
- Author
-
Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Bourcier, Valérie, Archambeaud, Isabelle, Perarnau, Jean Marc, Oberti, Frédéric, Roulot, Dominique, Moreno, Christophe, Louvet, Alexandre, Dao, Thong, Moirand, Romain, Goria, Odile, Nguyen-Khac, Eric, Carbonell, Nicolas, Antonini, Teresa Maria, Pol, Stanislas, De Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Péron, Jean Marie, Tran, Albert, Perlemuter, Gabriel, Amiot, Xavier, Zarski, Jean-Pierre, Beaugrand, Michel, Chevret, Sylvie, Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Bourcier, Valérie, Archambeaud, Isabelle, Perarnau, Jean Marc, Oberti, Frédéric, Roulot, Dominique, Moreno, Christophe, Louvet, Alexandre, Dao, Thong, Moirand, Romain, Goria, Odile, Nguyen-Khac, Eric, Carbonell, Nicolas, Antonini, Teresa Maria, Pol, Stanislas, De Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Péron, Jean Marie, Tran, Albert, Perlemuter, Gabriel, Amiot, Xavier, Zarski, Jean-Pierre, Beaugrand, Michel, and Chevret, Sylvie
- Abstract
Background & Aims: More than 90% of cases of hepatocellular carcinoma (HCC) occur in patients with cirrhosis, of which alcohol is a major cause. The CIRRAL cohort aimed to assess the burden of complications in patients with alcoholic cirrhosis, particularly the occurrence of HCC. Methods: Patients with biopsy-proven compensated alcoholic cirrhosis were included then prospectively followed. The main endpoint was the incidence of HCC. Secondary outcomes were incidence of hepatic focal lesions, overall survival (OS), liver-related mortality and event-free survival (EFS). Results: From October 2010 to April 2016, 652 patients were included in 22 French and Belgian centers. During follow-up (median 29 months), HCC was diagnosed in 43 patients. With the limitation derived from the uncertainty of consecutive patients’ inclusion and from a sizable proportion of dropouts (153/652), the incidence of HCC was 2.9 per 100 patient-years, and one- and two-year cumulative incidences of 1.8% and 5.2%, respectively. Although HCC fulfilled the Milan criteria in 33 cases (77%), only 24 patients (56%) underwent curative treatment. An explorative prognostic analysis showed that age, male gender, baseline alpha-fetoprotein, bilirubin and prothrombin were significantly associated with the risk of HCC occurrence. Among 73 deaths, 61 had a recorded cause and 27 were directly attributable to liver disease. At two years, OS, EFS and cumulative incidences of liver-related deaths were 93% (95% CI 90.5–95.4), 80.3% (95% CI 76.9–83.9), and 3.2% (95% CI 1.6–4.8) respectively. Conclusion: This large prospective cohort incompletely representative of the whole population with alcoholic cirrhosis showed: a) an annual incidence of HCC of up to 2.9 per 100 patient-years, suggesting that surveillance might be cost effective in these patients; b) a high proportion of HCC detected within the Milan criteria, but only one-half of detected HCC cases were referred for curative treatments; c) a two-year mortalit, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2018
20. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study
- Author
-
Costentin, Charlotte E., primary, Layese, Richard, additional, Bourcier, Valérie, additional, Cagnot, Carole, additional, Marcellin, Patrick, additional, Guyader, Dominique, additional, Pol, Stanislas, additional, Larrey, Dominique, additional, De Lédinghen, Victor, additional, Ouzan, Denis, additional, Zoulim, Fabien, additional, Roulot, Dominique, additional, Tran, Albert, additional, Bronowicki, Jean-Pierre, additional, Zarski, Jean-Pierre, additional, Riachi, Ghassan, additional, Calès, Paul, additional, Péron, Jean-Marie, additional, Alric, Laurent, additional, Bourlière, Marc, additional, Mathurin, Philippe, additional, Blanc, Jean-Frédéric, additional, Abergel, Armand, additional, Serfaty, Lawrence, additional, Mallat, Ariane, additional, Grangé, Jean-Didier, additional, Attali, Pierre, additional, Bacq, Yannick, additional, Wartelle, Claire, additional, Dao, Thông, additional, Thabut, Dominique, additional, Pilette, Christophe, additional, Silvain, Christine, additional, Christidis, Christos, additional, Nguyen-khac, Eric, additional, Bernard-Chabert, Brigitte, additional, Zucman, David, additional, Di Martino, Vincent, additional, Sutton, Angela, additional, Letouzé, Eric, additional, Imbeaud, Sandrine, additional, Zucman-Rossi, Jessica, additional, Audureau, Etienne, additional, Roudot-Thoraval, Françoise, additional, Nahon, Pierre, additional, Fontaine, Hélène, additional, Leroy, Vincent, additional, Dharancy, Sebastien, additional, Capron, Dominique, additional, Thiefin, Gérard, additional, and Hillaire, Sophie, additional
- Published
- 2018
- Full Text
- View/download PDF
21. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective
- Author
-
Alric, Laurent, primary, Ollivier-Hourmand, Isabelle, additional, Bérard, Emilie, additional, Hillaire, Sophie, additional, Guillaume, Maeva, additional, Vallet-Pichard, Anais, additional, Bernard-Chabert, Brigitte, additional, Loustaud-Ratti, Veronique, additional, Bourlière, Marc, additional, de Ledinghen, Victor, additional, Fouchard-Hubert, Isabelle, additional, Canva, Valerie, additional, Minello, Anne, additional, Nguyen-Khac, Eric, additional, Leroy, Vincent, additional, Saadoun, David, additional, Trias, Dominique, additional, Pol, Stanislas, additional, and Kamar, Nassim, additional
- Published
- 2018
- Full Text
- View/download PDF
22. Signaling lymphocytic activation molecules Slam and cancers: friends or foes?
- Author
-
Fouquet, Gregory, primary, Marcq, Ingrid, additional, Debuysscher, Véronique, additional, Bayry, Jagadeesh, additional, Rabbind Singh, Amrathlal, additional, Bengrine, Abderrahmane, additional, Nguyen-Khac, Eric, additional, Naassila, Mickael, additional, and Bouhlal, Hicham, additional
- Published
- 2018
- Full Text
- View/download PDF
23. Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs
- Author
-
Fouquet, Grégory, primary, Debuysscher, Véronique, additional, Ouled-Haddou, Hakim, additional, Eugenio, Mélanie Simoes, additional, Demey, Baptiste, additional, Singh, Amrathlal Rabbind, additional, Ossart, Christèle, additional, Bagami, Mohammed Al, additional, Regimbeau, Jean-Marc, additional, Nguyen-Khac, Eric, additional, Naassila, Mickael, additional, Marcq, Ingrid, additional, and Bouhlal, Hicham, additional
- Published
- 2016
- Full Text
- View/download PDF
24. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation
- Author
-
Bouhlal, Hicham, primary, Ouled-Haddou, Hakim, additional, Debuysscher, Véronique, additional, Singh, Amrathlal Rabbind, additional, Ossart, Christèle, additional, Reignier, Aline, additional, Hocini, Hakim, additional, Fouquet, Gregory, additional, Baghami, Mohammed Al, additional, Eugenio, Mélanie Simoes, additional, Nguyen-Khac, Eric, additional, Regimbeau, Jean-Marc, additional, and Marcq, Ingrid, additional
- Published
- 2016
- Full Text
- View/download PDF
25. Human and Experimental Evidence Supporting a Role for Osteopontin in Alcoholic Hepatitis
- Author
-
Morales-Ibanez, Oriol, Domínguez, Marlene, Ki, Sung H., Marcos, Miguel, Chaves, Javier F., Nguyen-Khac, Eric, Houchi, Hakim, Affò, Silvia, Sancho-Bru, Pau, Altamirano, José, Michelena, Javier, García-Pagán, Juan Carlos, Abraldes, Juan G., Arroyo, Vicente, Caballería, Juan, Laso, Francisco-Javier, Gao, Bin, and Bataller, Ramón
- Subjects
Male ,Mice ,stomatognathic system ,Hepatitis, Alcoholic ,Animals ,Humans ,Female ,Osteopontin ,Middle Aged ,Liver Diseases, Alcoholic ,Polymorphism, Single Nucleotide ,Severity of Illness Index ,Article - Abstract
We identified, in the transcriptome analysis of patients with alcoholic hepatitis (AH), osteopontin (OPN) as one of the most up-regulated genes. Here, we used a translational approach to investigate its pathogenic role. OPN hepatic gene expression was quantified in patients with AH and other liver diseases. OPN protein expression and processing were assessed by immmunohistochemistry, western blotting and enzyme-linked immunosorbent assay. OPN gene polymorphisms were evaluated in patients with alcoholic liver disease. The role of OPN was evaluated in OPN(-/-) mice with alcohol-induced liver injury. OPN biological actions were studied in human hepatic stellate cells (HSCs) and in precision-cut liver slices. Hepatic expression and serum levels of OPN were markedly increased in AH, compared to normal livers and other types of chronic liver diseases, and correlated with short-term survival. Serum levels of OPN also correlated with hepatic expression and disease severity. OPN was mainly expressed in areas with inflammation and fibrosis. Two proteases that process OPN (thrombin and matrix metalloproteinase 7) and cleaved OPN were increased in livers with AH. Patients with AH had a tendency of a lower frequency of the CC genotype of the +1239C single-nucleotide polymorphism of the OPN gene, compared to patients with alcohol abuse without liver disease. Importantly, OPN(-/-) mice were protected against alcohol-induced liver injury and showed decreased expression of inflammatory cytokines. Finally, OPN was induced by lipopolysaccharide and stimulated inflammatory actions in HSCs.Human and experimental data suggest a role for OPN in the pathogenesis of AH. Further studies should evaluate OPN as a potential therapeutic target.
- Published
- 2013
26. Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression
- Author
-
Marcq, Ingrid, primary, Nyga, Rémy, additional, Cartier, Flora, additional, Amrathlal, Rabbind Singh, additional, Ossart, Christèle, additional, Ouled-Haddou, Hakim, additional, Ghamlouch, Hussein, additional, Galmiche, Antoine, additional, Chatelain, Denis, additional, Lamotte, Luciane, additional, Debuysscher, Véronique, additional, Fuentes, Vincent, additional, Nguyen-Khac, Eric, additional, Regimbeau, Jean-Marc, additional, Marolleau, Jean-Pierre, additional, Latour, Sylvain, additional, and Bouhlal, Hicham, additional
- Published
- 2013
- Full Text
- View/download PDF
27. A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
- Author
-
Nguyen-Khac, Eric, primary, Lobry, Céline, additional, Chatelain, Denis, additional, Fuks, David, additional, Joly, Jean Paul, additional, Brevet, Marie, additional, Tramier, Blaise, additional, Mouly, Charlotte, additional, Hautefeuille, Vincent, additional, Chauffert, Bruno, additional, and Regimbeau, Jean Marc, additional
- Published
- 2013
- Full Text
- View/download PDF
28. The Treatment Response of Chronically Hepatitis C Virus-Infected Patients Depends on Interferon Concentration but Not on Interferon Gene Expression in Peripheral Blood Mononuclear Cells
- Author
-
François, Catherine, primary, Coulouarn, Cédric, additional, Descamps, Véronique, additional, Castelain, Sandrine, additional, Brochot, Etienne, additional, Baron, Agnès, additional, Duchaussoy, Isabelle, additional, Capron, Dominique, additional, Nguyen-Khac, Eric, additional, and Duverlie, Gilles, additional
- Published
- 2012
- Full Text
- View/download PDF
29. BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma
- Author
-
Galmiche, Antoine, primary, Ezzoukhry, Zakaria, additional, François, Catherine, additional, Louandre, Christophe, additional, Sabbagh, Charles, additional, Nguyen-Khac, Eric, additional, Descamps, Véronique, additional, Trouillet, Nathalie, additional, Godin, Corinne, additional, Regimbeau, Jean-Marc, additional, Joly, Jean-Paul, additional, Barbare, Jean-Claude, additional, Duverlie, Gilles, additional, Mazière, Jean-Claude, additional, and Chatelain, Denis, additional
- Published
- 2010
- Full Text
- View/download PDF
30. Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multicenter French study
- Author
-
Nguyen-Khac, Eric, primary, Ollivier, Isabelle, additional, Aparicio, Thomas, additional, Moullart, Véronique, additional, Hugentobler, Alexis, additional, Lebtahi, Rachida, additional, Lobry, Céline, additional, Susini, Christiane, additional, Duhamel, Christian, additional, Hommel, Séverine, additional, Cadranel, Jean François, additional, Joly, Jean-paul, additional, Barbare, Jean Claude, additional, Tramier, Blaise, additional, and Dupas, Jean Louis, additional
- Published
- 2009
- Full Text
- View/download PDF
31. A Pitfall in the Diagnosis of Unresectable Liver Metastases: Multiple Bile Duct Hamartomas (von Meyenburg Complexes)
- Author
-
Fuks, David, primary, Le Mouel, Jean-Philippe, additional, Chatelain, Denis, additional, Sabbagh, Charles, additional, Demuynck, Fabien, additional, Brevet, Marie, additional, Brehant, Olivier, additional, Nguyen-Khac, Eric, additional, Yzet, Thierry, additional, Dumont, Frederic, additional, Verhaeghe, Pierre, additional, and Regimbeau, Jean-Marc, additional
- Published
- 2009
- Full Text
- View/download PDF
32. The Treatment Response of Chronically Hepatitis C Virus-Infected Patients Depends on Interferon Concentration but Not on Interferon Gene Expression in Peripheral Blood Mononuclear Cells
- Author
-
François, Catherine, Coulouarn, Cédric, Descamps, Véronique, Castelain, Sandrine, Brochot, Etienne, Baron, Agnès, Duchaussoy, Isabelle, Capron, Dominique, Nguyen-Khac, Eric, and Duverlie, Gilles
- Abstract
ABSTRACTThe current treatment of chronic hepatitis C is based on pegylated alpha interferon (PEG-IFN-α) and ribavirin. The aim of this study was to identify biological and clinical variables related to IFN therapy that could predict patient outcome. The study enrolled 47 patients treated with PEG-IFN and ribavirin combined therapy. The interferon concentration was measured in serum by a bioassay. The expression of 93 interferon-regulated genes in peripheral blood mononuclear cells was quantified by real-time quantitative reverse transcription-PCR (RT-PCR) before and after 1 month of treatment. The interferon concentration in the serum was significantly lower in nonresponders than in sustained virological responders. Moreover, a significant correlation was identified between interferon concentration and interferon exposition as well as body weight. The analysis of interferon-inducible genes in peripheral blood mononuclear cells among the genes tested did not permit the prediction of treatment outcome. In conclusion, the better option seems to be to treat patients with weight-adjusted PEG-IFN doses, particularly for patients with high weight who are treated with PEG-IFN-α2a. Although the peripheral blood mononuclear cell samples are the easiest to obtain, the measurement of interferon-inducible genes seems not be the best strategy to predict treatment outcome.
- Published
- 2011
- Full Text
- View/download PDF
33. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Author
-
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome, David Sheridan, Muhammad Y Sheikh, James Trotter, Whitfield Knapple, Eric Lawitz, Manal F Abdelmalek, Kris V Kowdley, Aldo J Montano-Loza, Jerome Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh MacConell, Reshma Shringarpure, Stephen Harrison, Arun J Sanyal, Manal Abdelmalek, Gary Abrams, Humberto Aguilar, Aijaz Ahmed, Elmar Aigner, Guruprasad Aithal, Aftab Ala, William Alazawi, Agustin Albillos, Michael Allison, Sfa Al-Shamma, Raul Andrade, Pietro Andreone, Mario Angelico, Victor Ankoma-Sey, Quentin Anstee, Rodolphe Anty, Victor Araya, Juan Ignacio Arenas Ruiz, Perttu Arkkila, Marty Arora, Tarik Asselah, Jennifer Au, Oyekoya Ayonrinde, Robert James Bailey, Maya Balakrishnan, Kiran Bambha, Meena Bansal, Sidney Barritt, John Bate, Jorge Beato, Jaideep Behari, Pablo Bellot, Ziv Ben Ari, Michael Bennett, Marina Berenguer, Benedetta Terziroli Beretta-Piccoli, Thomas Berg, Maurizio Bonacini, Lucia Bonet, Brian Borg, Marc Bourliere, William Bowman, David Bradley, Marija Brankovic, Marius Braun, Jean-Pierre Bronowicki, Savino Bruno, Cindy Cai, Amy Calderon, José Luis Calleja Panero, Elizabeth Carey, Michal Carmiel, Jose Antonio Carrión, Matthew Cave, Cristina Chagas, Tawfik Chami, Alan Chang, Allan Coates, Jeremy Cobbold, Charlote Costentin, Kathleen Corey, Lynsey Corless, Javier Crespo, Oscar Cruz Pereira, Victor de Ledinghen, Andrew deLemos, Moises Diago, Mamie Dong, Jean-François Dufour, Predrag Dugalic, Winston Dunn, Magby Elkhashab, Michael Epstein, Maria Desamparados Escudero-Garcia, Ohad Etzion, Larry Evans, Robert Falcone, Conrado Fernandez, Jose Ferreira, Scott Fink, Kevin Finnegan, Roberto Firpi-Morell, Annarosa Floreani, Thierry Fontanges, Ryan Ford, Ewan Forrest, Andrew Fowell, Anna Ludovica Fracanzani, Sven Francque, Bradley Freilich, Juan Frias, Michael Fuchs, Javier Fuentes, Michael Galambos, Juan Gallegos, Anja Geerts, Jacob George, Maged Ghali, Reem Ghalib, Pierre Gholam, Pere Gines, Norman Gitlin, Tobias Goeser, John Goff, Stuart Gordon, Frederic Gordon, Odile Goria, Shaun Greer, Alla Grigorian, Henning Gronbaek, Maeva Guillaume, Naresh Gunaratnam, Dina Halegoua-De Marzio, Bilal Hameed, Stephanie Hametner, James Hamilton, Marek Hartleb, Tarek Hassanein, Dieter Häussinger, Paul Hellstern, Robert Herring, Eva Heurich, Christophe Hezode, Holger Hinrichsen, Peter Holland Fischer, Yves Horsmans, Jonathan Huang, Hyder Hussaini, Antoine Jakiche, Lennox Jeffers, Blake Jones, Rosa Jorge, Francisco Jorquera, Shoba Joshi, Alisan Kahraman, Kelly Kaita, Nicholas Karyotakis, Zeid Kayali, Stergios Kechagias, Thomas Kepczyk, Mandana Khalili, Hicham Khallafi, Johannes Kluwe, Anita Kohli, Kevin Korenblat, Kris Kowdley, Aleksander Krag, Richard Krause, Andreas Kremer, Karen Krok, Miodrag Krstic, Marcelo Kugelmas, Sonal Kumar, Scott Kuwada, Damien Labarriere, Michelle Lai, Wim Laleman, Pietro Lampertico, Alice Lee, Vincent Leroy, Steven Lidofsky, Tina Huey Lim, Joseph Lim, Donald Lipkis, Ester Little, Amadeo Lonardo, Michelle Long, Velimir Anthony Christopher Luketic, Yoav Lurie, Guilherme Macedo, Joana Magalhaes, Mihály Makara, Benedict Maliakkal, Michael Manns, Pinelopi Manousou, Parvez Mantry, Giulio Marchesini, Carla Marinho, Paul Marotta, Hanns-Ulrich Marschall, Linda Martinez, Marlyn Mayo, Mark McCullen, William McLaughlin, Uta Merle, Raphael Merriman, Apurva Modi, Esther Molina, Aldo Montano-Loza, Carlos Monteverde, Amilcar Morales Cardona, Sulleman Moreea, Christophe Moreno, Filomena Morisco, Abdullah Mubarak, Beat Muellhaupt, Sandeep Mukherjee, Tobias Müller, Aleksandar Nagorni, Jahnavi Naik, Guy Neff, Moises Nevah, Philip Newsome, Eric Nguyen-Khac, Mazen Noureddin, Jude Oben, Hans Orlent, James Orr, Grisell Ortiz-Lasanta, Violaine Ozenne, Prashant Pandya, Angelo Paredes, James Park, Joykumar Patel, Keyur Patel, Sonali Paul, Heather Patton, Markus Peck-Radosavljevic, Salvatore Petta, Stephen Pianko, Anna Piekarska, Neville Pimstone, Joseph Pisegna, Paul Pockros, Stanislas Pol, Michael Porayko, John Poulos, David Pound, Joe Pouzar, Jose Presa Ramos, Nikolaos Pyrsopoulos, Nila Rafiq, Kate Muller, Alnoor Ramji, Ravi Ravinuthala, Chakradhar Reddy, Gautham Reddy K G, K. Rajender Reddy K R, Frederic Regenstein, Robert Reindollar, Justin Reynolds, Andres Riera, Jose Rivera Acosta, Geert Robaeys, Stuart Roberts, Federico Rodriguez-Perez, Sandor Romero, Manuel Romero-Gomez, Raymond Rubin, Mariagrazia Rumi, Simon Rushbrook, Christian Rust, Michael Ryan, Rifaat Safadi, Adnan Said, Kimmo Salminen, Didier Samuel, John Santoro, Arun Sanyal, Souvik Sarkar, Cynthia Schaeffer, Jörn Schattenberg, Ingolf Schiefke, Eugene Schiff, Wolfgang Schmidt, Jeffrey Schneider, Jeoffrey Schouten, Michael Schultz, Giada Sebastiani, David Semela, Thomas Sepe, Aasim Sheikh, Muhammad Sheikh, Kenneth Sherman, Oren Shibolet, Mitchell Shiffman, Asma Siddique, Cyril Sieberhagen, Samuel Sigal, Katarzyna Sikorska, Krzysztof Simon, Marie Sinclair, Richard Skoien, Joel Solis, Siddharth Sood, Bob Souder, James Spivey, Per Stal, Laura Stinton, Simone Strasser, Petar Svorcan, Gyongzi Szabo, Andrew Talal, Edward Tam, Brent Tetri, Paul Thuluvath, Hillel Tobias, Krzysztof Tomasiewicz, Dawn Torres, Albert Tran, Michael Trauner, Christian Trautwein, Emanuel Tsochatzis, Esther Unitt, Victor Vargas, Istvan Varkonyi, Ella Veitsman, Umberto Vespasiani Gentilucci, David Victor, John Vierling, Catherine Vincent, Aron Vincze, Manfred von der Ohe, Natasha Von Roenn, Raj Vuppalanchi, Michael Waters, Kymberly Watt, Julia Wattacheril, Martin Weltman, Amanda Wieland, Gregory Wiener, Alonzo Williams A, Jeffrey Williams J, Jason Wilson, Maria Yataco, Eric Yoshida, Ziad Younes, Liyun Yuan, Adam Zivony, Donald Zogg, Heinz Zoller, Fabien Zoulim, Eli Zuckerman, Massimo Zuin, Younossi Z.M., Ratziu V., Loomba R., Rinella M., Anstee Q.M., Goodman Z., Bedossa P., Geier A., Beckebaum S., Newsome P.N., Sheridan D., Sheikh M.Y., Trotter J., Knapple W., Lawitz E., Abdelmalek M.F., Kowdley K.V., Montano-Loza A.J., Boursier J., Mathurin P., Bugianesi E., Mazzella G., Olveira A., Cortez-Pinto H., Graupera I., Orr D., Gluud L.L., Dufour J.-F., Shapiro D., Campagna J., Zaru L., MacConell L., Shringarpure R., Harrison S., Sanyal A.J., Abdelmalek M., Abrams G., Aguilar H., Ahmed A., Aigner E., Aithal G., Ala A., Alazawi W., Albillos A., Allison M., Al-Shamma S., Andrade R., Andreone P., Angelico M., Ankoma-Sey V., Anstee Q., Anty R., Araya V., Arenas Ruiz J.I., Arkkila P., Arora M., Asselah T., Au J., Ayonrinde O., Bailey R.J., Balakrishnan M., Bambha K., Bansal M., Barritt S., Bate J., Beato J., Behari J., Bellot P., Ben Ari Z., Bennett M., Berenguer M., Beretta-Piccoli B.T., Berg T., Bonacini M., Bonet L., Borg B., Bourliere M., Bowman W., Bradley D., Brankovic M., Braun M., Bronowicki J.-P., Bruno S., Cai C., Calleja Panero J.L., Carey E., Carmiel M., Carrion J.A., Cave M., Chagas C., Chami T., Chang A., Coates A., Cobbold J., Corey K., Corless L., Crespo J., Cruz Pereira O., de Ledinghen V., deLemos A., Diago M., Dugalic P., Dunn W., Elkhashab M., Epstein M., Escudero-Garcia M.D., Etzion O., Evans L., Falcone R., Fernandez C., Ferreira J., Fink S., Finnegan K., Firpi-Morell R., Floreani A., Fontanges T., Ford R., Forrest E., Fowell A., Fracanzani A.L., Francque S., Freilich B., Frias J., Fuchs M., Fuentes J., Galambos M., Gallegos J., Geerts A., George J., Ghali M., Ghalib R., Gholam P., Gines P., Gitlin N., Goeser T., Goff J., Gordon S., Gordon F., Goria O., Greer S., Grigorian A., Gronbaek H., Guillaume M., Gunaratnam N., Halegoua-De Marzio D., Hameed B., Hametner S., Hamilton J., Hartleb M., Hassanein T., Haussinger D., Hellstern P., Herring R., Heurich E., Hezode C., Hinrichsen H., Holland Fischer P., Horsmans Y., Huang J., Jakiche A., Jeffers L., Jones B., Jorge R., Jorquera F., Kahraman A., Kaita K., Karyotakis N., Kayali Z., Kechagias S., Kepczyk T., Khalili M., Khallafi H., Kluwe J., Kohli A., Korenblat K., Kowdley K., Krag A., Krause R., Kremer A., Krok K., Krstic M., Kugelmas M., Kumar S., Labarriere D., Lai M., Lampertico P., Lee A., Leroy V., Lidofsky S., Lim T.H., Lim J., Lipkis D., Little E., Lonardo A., Long M., Lurie Y., Macedo G., Makara M., Maliakkal B., Manns M., Manousou P., Mantry P., Marchesini G., Marinho C., Marotta P., Marschall H.-U., Mayo M., McCullen M., McLaughlin W., Merriman R., Modi A., Molina E., Montano-Loza A., Monteverde C., Moreea S., Moreno C., Morisco F., Mubarak A., Muellhaupt B., Mukherjee S., Muller T., Nagorni A., Naik J., Neff G., Nevah M., Newsome P., Nguyen-Khac E., Noureddin M., Oben J., Orlent H., Orr J., Ortiz-Lasanta G., Ozenne V., Pandya P., Paredes A., Park J., Patel J., Patel K., Uta M., Patton H., Peck-Radosavljevic M., Petta S., Pianko S., Piekarska A., Pimstone N., Pockros P., Pol S., Porayko M., Poulos J., Pound D., Pouzar J., Presa Ramos J., Pyrsopoulos N., Rafiq N., Muller K., Ramji A., Ravinuthala R., Reddy C., Reddy K G G., Reddy K R K.R., Regenstein F., Reindollar R., Riera A., Rivera Acosta J., Robaeys G., Roberts S., Rodriguez-Perez F., Romero-Gomez M., Rubin R., Rumi M., Rushbrook S., Rust C., Ryan M., Safadi R., Said A., Salminen K., Samuel D., Santoro J., Sanyal A., Sarkar S., Schaeffer C., Schattenberg J., Schiefke I., Schiff E., Schmidt W., Schneider J., Schouten J., Schultz M., Sebastiani G., Semela D., Sepe T., Sheikh A., Sheikh M., Sherman K., Shibolet O., Shiffman M., Siddique A., Sieberhagen C., Sigal S., Sikorska K., Simon K., Sinclair M., Skoien R., Solis J., Sood S., Souder B., Spivey J., Stal P., Stinton L., Strasser S., Svorcan P., Szabo G., Talal A., Tam E., Tetri B., Thuluvath P., Tobias H., Tomasiewicz K., Torres D., Trauner M., Trautwein C., Tsochatzis E., Unitt E., Vargas V., Varkonyi I., Veitsman E., Vespasiani Gentilucci U., Victor D., Vierling J., Vincent C., Vincze A., von der Ohe M., Von Roenn N., Vuppalanchi R., Waters M., Watt K., Weltman M., Wieland A., Wiener G., Williams A A., Williams J J., Wilson J., Yataco M., Yoshida E., Younes Z., Yuan L., Zivony A., Zogg D., Zoller H., Zoulim F., Zuckerman E., Zuin M., Repositório da Universidade de Lisboa, Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., Sheridan, D., Sheikh, M. Y., Trotter, J., Knapple, W., Lawitz, E., Abdelmalek, M. F., Kowdley, K. V., Montano-Loza, A. J., Boursier, J., Mathurin, P., Bugianesi, E., Mazzella, G., Olveira, A., Cortez-Pinto, H., Graupera, I., Orr, D., Gluud, L. L., Dufour, J. -F., Shapiro, D., Campagna, J., Zaru, L., Macconell, L., Shringarpure, R., Harrison, S., Sanyal, A. J., Abdelmalek, M., Abrams, G., Aguilar, H., Ahmed, A., Aigner, E., Aithal, G., Ala, A., Alazawi, W., Albillos, A., Allison, M., Al-Shamma, S., Andrade, R., Andreone, P., Angelico, M., Ankoma-Sey, V., Anstee, Q., Anty, R., Araya, V., Arenas Ruiz, J. I., Arkkila, P., Arora, M., Asselah, T., Au, J., Ayonrinde, O., Bailey, R. J., Balakrishnan, M., Bambha, K., Bansal, M., Barritt, S., Bate, J., Beato, J., Behari, J., Bellot, P., Ben Ari, Z., Bennett, M., Berenguer, M., Beretta-Piccoli, B. T., Berg, T., Bonacini, M., Bonet, L., Borg, B., Bourliere, M., Bowman, W., Bradley, D., Brankovic, M., Braun, M., Bronowicki, J. -P., Bruno, S., Cai, C., Calleja Panero, J. L., Carey, E., Carmiel, M., Carrion, J. A., Cave, M., Chagas, C., Chami, T., Chang, A., Coates, A., Cobbold, J., Corey, K., Corless, L., Crespo, J., Cruz Pereira, O., de Ledinghen, V., Delemos, A., Diago, M., Dugalic, P., Dunn, W., Elkhashab, M., Epstein, M., Escudero-Garcia, M. D., Etzion, O., Evans, L., Falcone, R., Fernandez, C., Ferreira, J., Fink, S., Finnegan, K., Firpi-Morell, R., Floreani, A., Fontanges, T., Ford, R., Forrest, E., Fowell, A., Fracanzani, A. L., Francque, S., Freilich, B., Frias, J., Fuchs, M., Fuentes, J., Galambos, M., Gallegos, J., Geerts, A., George, J., Ghali, M., Ghalib, R., Gholam, P., Gines, P., Gitlin, N., Goeser, T., Goff, J., Gordon, S., Gordon, F., Goria, O., Greer, S., Grigorian, A., Gronbaek, H., Guillaume, M., Gunaratnam, N., Halegoua-De Marzio, D., Hameed, B., Hametner, S., Hamilton, J., Hartleb, M., Hassanein, T., Haussinger, D., Hellstern, P., Herring, R., Heurich, E., Hezode, C., Hinrichsen, H., Holland Fischer, P., Horsmans, Y., Huang, J., Jakiche, A., Jeffers, L., Jones, B., Jorge, R., Jorquera, F., Kahraman, A., Kaita, K., Karyotakis, N., Kayali, Z., Kechagias, S., Kepczyk, T., Khalili, M., Khallafi, H., Kluwe, J., Kohli, A., Korenblat, K., Kowdley, K., Krag, A., Krause, R., Kremer, A., Krok, K., Krstic, M., Kugelmas, M., Kumar, S., Labarriere, D., Lai, M., Lampertico, P., Lee, A., Leroy, V., Lidofsky, S., Lim, T. H., Lim, J., Lipkis, D., Little, E., Lonardo, A., Long, M., Lurie, Y., Macedo, G., Makara, M., Maliakkal, B., Manns, M., Manousou, P., Mantry, P., Marchesini, G., Marinho, C., Marotta, P., Marschall, H. -U., Mayo, M., Mccullen, M., Mclaughlin, W., Merriman, R., Modi, A., Molina, E., Montano-Loza, A., Monteverde, C., Moreea, S., Moreno, C., Morisco, F., Mubarak, A., Muellhaupt, B., Mukherjee, S., Muller, T., Nagorni, A., Naik, J., Neff, G., Nevah, M., Newsome, P., Nguyen-Khac, E., Noureddin, M., Oben, J., Orlent, H., Orr, J., Ortiz-Lasanta, G., Ozenne, V., Pandya, P., Paredes, A., Park, J., Patel, J., Patel, K., Uta, M., Patton, H., Peck-Radosavljevic, M., Petta, S., Pianko, S., Piekarska, A., Pimstone, N., Pockros, P., Pol, S., Porayko, M., Poulos, J., Pound, D., Pouzar, J., Presa Ramos, J., Pyrsopoulos, N., Rafiq, N., Muller, K., Ramji, A., Ravinuthala, R., Reddy, C., Reddy K G, G., Reddy K R, K. R., Regenstein, F., Reindollar, R., Riera, A., Rivera Acosta, J., Robaeys, G., Roberts, S., Rodriguez-Perez, F., Romero-Gomez, M., Rubin, R., Rumi, M., Rushbrook, S., Rust, C., Ryan, M., Safadi, R., Said, A., Salminen, K., Samuel, D., Santoro, J., Sanyal, A., Sarkar, S., Schaeffer, C., Schattenberg, J., Schiefke, I., Schiff, E., Schmidt, W., Schneider, J., Schouten, J., Schultz, M., Sebastiani, G., Semela, D., Sepe, T., Sheikh, A., Sheikh, M., Sherman, K., Shibolet, O., Shiffman, M., Siddique, A., Sieberhagen, C., Sigal, S., Sikorska, K., Simon, K., Sinclair, M., Skoien, R., Solis, J., Sood, S., Souder, B., Spivey, J., Stal, P., Stinton, L., Strasser, S., Svorcan, P., Szabo, G., Talal, A., Tam, E., Tetri, B., Thuluvath, P., Tobias, H., Tomasiewicz, K., Torres, D., Trauner, M., Trautwein, C., Tsochatzis, E., Unitt, E., Vargas, V., Varkonyi, I., Veitsman, E., Vespasiani Gentilucci, U., Victor, D., Vierling, J., Vincent, C., Vincze, A., von der Ohe, M., Von Roenn, N., Vuppalanchi, R., Waters, M., Watt, K., Weltman, M., Wieland, A., Wiener, G., Williams A, A., Williams J, J., Wilson, J., Yataco, M., Yoshida, E., Younes, Z., Yuan, L., Zivony, A., Zogg, D., Zoller, H., Zoulim, F., Zuckerman, E., Zuin, M., Younossi, Zobair M, Ratziu, Vlad, Loomba, Rohit, Rinella, Mary, Anstee, Quentin M, Goodman, Zachary, Bedossa, Pierre, Geier, Andrea, Beckebaum, Susanne, Newsome, Philip N, Sheridan, David, Sheikh, Muhammad Y, Trotter, Jame, Knapple, Whitfield, Lawitz, Eric, Abdelmalek, Manal F, Kowdley, Kris V, Montano-Loza, Aldo J, Boursier, Jerome, Mathurin, Philippe, Bugianesi, Elisabetta, Mazzella, Giuseppe, Olveira, Antonio, Cortez-Pinto, Helena, Graupera, Isabel, Orr, David, Gluud, Lise Lotte, Dufour, Jean-Francoi, Shapiro, David, Campagna, Jason, Zaru, Luna, MacConell, Leigh, Shringarpure, Reshma, Harrison, Stephen, Sanyal, Arun J, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Ahmed, Aijaz, Aigner, Elmar, Aithal, Guruprasad, Ala, Aftab, Alazawi, William, Albillos, Agustin, Allison, Michael, Al-Shamma, Sfa, Andrade, Raul, Andreone, Pietro, Angelico, Mario, Ankoma-Sey, Victor, Anstee, Quentin, Anty, Rodolphe, Araya, Victor, Arenas Ruiz, Juan Ignacio, Arkkila, Perttu, Arora, Marty, Asselah, Tarik, Au, Jennifer, Ayonrinde, Oyekoya, Bailey, Robert Jame, Balakrishnan, Maya, Bambha, Kiran, Bansal, Meena, Barritt, Sidney, Bate, John, Beato, Jorge, Behari, Jaideep, Bellot, Pablo, Ben Ari, Ziv, Bennett, Michael, Berenguer, Marina, Beretta-Piccoli, Benedetta Terziroli, Berg, Thoma, Bonacini, Maurizio, Bonet, Lucia, Borg, Brian, Bourliere, Marc, Bowman, William, Bradley, David, Brankovic, Marija, Braun, Mariu, Bronowicki, Jean-Pierre, Bruno, Savino, Cai, Cindy, Calleja Panero, José Lui, Carey, Elizabeth, Carmiel, Michal, Carrión, Jose Antonio, Cave, Matthew, Chagas, Cristina, Chami, Tawfik, Chang, Alan, Coates, Allan, Cobbold, Jeremy, Corey, Kathleen, Corless, Lynsey, Crespo, Javier, Cruz Pereira, Oscar, de Ledinghen, Victor, deLemos, Andrew, Diago, Moise, Dufour, Jean-Françoi, Dugalic, Predrag, Dunn, Winston, Elkhashab, Magby, Epstein, Michael, Escudero-Garcia, Maria Desamparado, Etzion, Ohad, Evans, Larry, Falcone, Robert, Fernandez, Conrado, Ferreira, Jose, Fink, Scott, Finnegan, Kevin, Firpi-Morell, Roberto, Floreani, Annarosa, Fontanges, Thierry, Ford, Ryan, Forrest, Ewan, Fowell, Andrew, Fracanzani, Anna Ludovica, Francque, Sven, Freilich, Bradley, Frias, Juan, Fuchs, Michael, Fuentes, Javier, Galambos, Michael, Gallegos, Juan, Geerts, Anja, George, Jacob, Ghali, Maged, Ghalib, Reem, Gholam, Pierre, Gines, Pere, Gitlin, Norman, Goeser, Tobia, Goff, John, Gordon, Stuart, Gordon, Frederic, Goria, Odile, Greer, Shaun, Grigorian, Alla, Gronbaek, Henning, Guillaume, Maeva, Gunaratnam, Naresh, Halegoua-De Marzio, Dina, Hameed, Bilal, Hametner, Stephanie, Hamilton, Jame, Hartleb, Marek, Hassanein, Tarek, Häussinger, Dieter, Hellstern, Paul, Herring, Robert, Heurich, Eva, Hezode, Christophe, Hinrichsen, Holger, Holland Fischer, Peter, Horsmans, Yve, Huang, Jonathan, Jakiche, Antoine, Jeffers, Lennox, Jones, Blake, Jorge, Rosa, Jorquera, Francisco, Kahraman, Alisan, Kaita, Kelly, Karyotakis, Nichola, Kayali, Zeid, Kechagias, Stergio, Kepczyk, Thoma, Khalili, Mandana, Khallafi, Hicham, Kluwe, Johanne, Kohli, Anita, Korenblat, Kevin, Kowdley, Kri, Krag, Aleksander, Krause, Richard, Kremer, Andrea, Krok, Karen, Krstic, Miodrag, Kugelmas, Marcelo, Kumar, Sonal, Labarriere, Damien, Lai, Michelle, Lampertico, Pietro, Lee, Alice, Leroy, Vincent, Lidofsky, Steven, Lim, Tina Huey, Lim, Joseph, Lipkis, Donald, Little, Ester, Lonardo, Amadeo, Long, Michelle, Lurie, Yoav, Macedo, Guilherme, Makara, Mihály, Maliakkal, Benedict, Manns, Michael, Manousou, Pinelopi, Mantry, Parvez, Marchesini, Giulio, Marinho, Carla, Marotta, Paul, Marschall, Hanns-Ulrich, Mayo, Marlyn, McCullen, Mark, McLaughlin, William, Merriman, Raphael, Modi, Apurva, Molina, Esther, Montano-Loza, Aldo, Monteverde, Carlo, Moreea, Sulleman, Moreno, Christophe, Morisco, Filomena, Mubarak, Abdullah, Muellhaupt, Beat, Mukherjee, Sandeep, Müller, Tobia, Nagorni, Aleksandar, Naik, Jahnavi, Neff, Guy, Nevah, Moise, Newsome, Philip, Nguyen-Khac, Eric, Noureddin, Mazen, Oben, Jude, Orlent, Han, Orr, Jame, Ortiz-Lasanta, Grisell, Ozenne, Violaine, Pandya, Prashant, Paredes, Angelo, Park, Jame, Patel, Joykumar, Patel, Keyur, Uta, Merle, Patton, Heather, Peck-Radosavljevic, Marku, Petta, Salvatore, Pianko, Stephen, Piekarska, Anna, Pimstone, Neville, Pockros, Paul, Pol, Stanisla, Porayko, Michael, Poulos, John, Pound, David, Pouzar, Joe, Presa Ramos, Jose, Pyrsopoulos, Nikolao, Rafiq, Nila, Muller, Kate, Ramji, Alnoor, Ravinuthala, Ravi, Reddy, Chakradhar, Reddy K G, Gautham, Reddy K R, K. Rajender, Regenstein, Frederic, Reindollar, Robert, Riera, Andre, Rivera Acosta, Jose, Robaeys, Geert, Roberts, Stuart, Rodriguez-Perez, Federico, Romero-Gomez, Manuel, Rubin, Raymond, Rumi, Mariagrazia, Rushbrook, Simon, Rust, Christian, Ryan, Michael, Safadi, Rifaat, Said, Adnan, Salminen, Kimmo, Samuel, Didier, Santoro, John, Sanyal, Arun, Sarkar, Souvik, Schaeffer, Cynthia, Schattenberg, Jörn, Schiefke, Ingolf, Schiff, Eugene, Schmidt, Wolfgang, Schneider, Jeffrey, Schouten, Jeoffrey, Schultz, Michael, Sebastiani, Giada, Semela, David, Sepe, Thoma, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shibolet, Oren, Shiffman, Mitchell, Siddique, Asma, Sieberhagen, Cyril, Sigal, Samuel, Sikorska, Katarzyna, Simon, Krzysztof, Sinclair, Marie, Skoien, Richard, Solis, Joel, Sood, Siddharth, Souder, Bob, Spivey, Jame, Stal, Per, Stinton, Laura, Strasser, Simone, Svorcan, Petar, Szabo, Gyongzi, Talal, Andrew, Tam, Edward, Tetri, Brent, Thuluvath, Paul, Tobias, Hillel, Tomasiewicz, Krzysztof, Torres, Dawn, Trauner, Michael, Trautwein, Christian, Tsochatzis, Emanuel, Unitt, Esther, Vargas, Victor, Varkonyi, Istvan, Veitsman, Ella, Vespasiani Gentilucci, Umberto, Victor, David, Vierling, John, Vincent, Catherine, Vincze, Aron, von der Ohe, Manfred, Von Roenn, Natasha, Vuppalanchi, Raj, Waters, Michael, Watt, Kymberly, Weltman, Martin, Wieland, Amanda, Wiener, Gregory, Williams A, Alonzo, Williams J, Jeffrey, Wilson, Jason, Yataco, Maria, Yoshida, Eric, Younes, Ziad, Yuan, Liyun, Zivony, Adam, Zogg, Donald, Zoller, Heinz, Zoulim, Fabien, Zuckerman, Eli, Zuin, Massimo, and REGENERATE Study Investigators
- Subjects
Male ,Biopsy ,Clinical Trial, Phase III ,Administration, Oral ,030204 cardiovascular system & hematology ,Chronic liver disease ,Settore MED/04 ,Biomarkers/analysis ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Liver Function Tests ,Non-alcoholic Fatty Liver Disease ,Clinical endpoint ,Medicine ,030212 general & internal medicine ,610 Medicine & health ,Chenodeoxycholic Acid/administration & dosage ,education.field_of_study ,Liver Function Test ,Research Support, Non-U.S. Gov't ,Fatty liver ,Obeticholic acid ,NASH, OBETICHOLIC ACID ,General Medicine ,Middle Aged ,Multicenter Study ,Randomized Controlled Trial ,Administration ,Female ,Biomarkers ,Chenodeoxycholic Acid ,Double-Blind Method ,Humans ,Human ,Oral ,medicine.medical_specialty ,Population ,Placebo ,03 medical and health sciences ,Research Support, N.I.H., Extramural ,Internal medicine ,Journal Article ,education ,Intention-to-treat analysis ,business.industry ,Biomarker ,Interim analysis ,medicine.disease ,Non-alcoholic Fatty Liver Disease/drug therapy ,chemistry ,Human medicine ,business - Abstract
© 2019 Elsevier Ltd. All rights reserved., Background: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods: In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings: Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation: Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes.
- Published
- 2019
- Full Text
- View/download PDF
34. Serum bile acids profiles are altered without change of the gut microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis.
- Author
-
Esparteiro D, Fouquet G, Courtois A, Jedraszak G, Marticho L, Gourdel M, Billon-Crossouard S, Croyal M, Naassila M, Nguyen-Khac E, and Marcq I
- Subjects
- Humans, Male, Middle Aged, Female, Retrospective Studies, Adult, Bacteria classification, Bacteria genetics, Bacteria isolation & purification, Bacteria drug effects, Fatty Acids, Volatile metabolism, Fatty Acids, Volatile blood, Carrier Proteins genetics, Carrier Proteins blood, Acute-Phase Proteins metabolism, Membrane Glycoproteins blood, Membrane Glycoproteins genetics, Aged, Metagenomics, Gastrointestinal Microbiome drug effects, Hepatitis, Alcoholic drug therapy, Hepatitis, Alcoholic blood, Feces microbiology, Feces chemistry, Bile Acids and Salts blood, Bile Acids and Salts metabolism, Prednisolone administration & dosage
- Abstract
Severe Alcoholic Hepatitis (sAH) is an acute form of liver injury caused by chronic and heavy alcohol drinking. A one-month corticosteroids course is the only sAH reference treatment, and its interactions with the Gut Microbiota (GM), which is a key contributor to liver injury, remain unknown. To evaluate the evolution of the GM in sAH patients, we retrospectively investigated the composition of the GM of 27 sAH patients at the Amiens University Hospital before (D0) and after (D7) a 7-day corticotherapy course using fecal metagenomics sequencing. We also quantified fecal Short-Chain Fatty Acids (SCFA) and fecal and serum Bile Acids (BA), as well as serum Lipopolysaccharide-Binding Protein (LBP). Overall, the community and taxonomical analyses did not reveal any GM evolution between D0 and D7, nor did the SCFA profiles analysis. However, in serum but not fecal samples, the ratio of glyco-conjugated to tauro-conjugated BA was significantly reduced at D7, independently of the response to treatment, while two BA were enriched in non-responder patients. LBP concentration significantly diminished between D0 and D7, which may indicate an improvement of the gut barrier. The stability of the GM of sAH is interesting in the perspective of new treatments based on GM modulation.
- Published
- 2024
- Full Text
- View/download PDF
35. Alfapump ® implantable device in management of refractory ascites: An update.
- Author
-
Weil-Verhoeven D, Di Martino V, Stirnimann G, Cervoni JP, Nguyen-Khac E, and Thévenot T
- Abstract
Refractory ascites (RA) is a frequent and life-threatening complication of cirrhosis. In selected patients with RA, transjugular intrahepatic portosystemic shunt (TIPS) placement and liver transplantation (LT) are currently considered the best therapeutic alternatives to repeated large volume paracentesis. In patients with a contraindication to TIPS or LT, the alfapump
® system (Sequana Medical, Ghent, Belgium) has been developed to reduce the need for iterative paracentesis, and consequently to improve the quality of life and nutritional status. We report here recent data on technical progress made since the first implantation, the efficacy and tolerance of the device, the position of the pump in the therapeutic arsenal for refractory ascites, and the grey areas that remain to be clarified regarding the optimal selection of patients who are potential candidates for this treatment., Competing Interests: Conflict-of-interest statement: Stirnimann G has received support for travel and meeting attendance, served as a speaker, and participated in Advisory Boards for Sequana Medical. There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
36. Low incidence of spontaneous bacterial peritonitis in asymptomatic cirrhotic outpatients.
- Author
-
Cadranel JF, Nousbaum JB, Bessaguet C, Nahon P, Nguyen-Khac E, Moreau R, Thévenot T, Silvain C, Bureau C, Nouel O, Pilette C, Paupard T, Pauwels A, Sapey T, Grangé JD, and Tran A
- Abstract
Aim: To compare the incidence of spontaneous bacterial peritonitis in cirrhotic outpatients and inpatients undergoing therapeutic paracentesis, Methods: From January 1 to May 31, 2004, 1041 patients from 70 different hospitals underwent 2123 therapeutic abdominal paracentesis (AP) performed as a outpatient procedure in 355 and as inpatient procedure in 686 cases respectively. The following parameters were compared prospectively between outpatients and inpatients: spontaneous bacterial peritonitis (SBP) prevalence, age, gender, cause of cirrhosis, symptoms, score and grade according to Child-Pugh classification, cirrhosis complications, antibiotics treatment, serum creatinine, platelet count and ascitic protein concentration., Results: SBP was observed in 91 patients. In the whole population the SBP prevalence was 8.7% (95%CI: 7.2-10.6) it was 11.7% (95%CI: 9.5-14.3) in inpatients and 3.1% (95%CI: 1.7-5.5) in outpatients (P < 0.00001). SBP prevalence was 8.3% (95%CI: 4.3-15.6) in symptomatic outpatients vs 1.2% (95%CI: 0.4-3.4) in asymptomatic outpatients (P < 0.002). Patients undergoing outpatient AP were significantly different from those undergoing inpatient AP; they were older (61.1 ± 11.1 years vs 59.4 ± 11.7 years; P = 0.028), cause of cirrhosis was less often alcohol (83 .7 vs 88.2%; P < 0.001), Child-Pugh score was lower (8.9 vs 10.1; P < 0.001) and more often B than C (63.7% vs 38%; P < 0.001). In addition, in outpatients the platelet count was higher (161 ± 93 Giga/L vs 143 ± 89 Giga/L; P = 0.003), serum total bilirubin concentration was lower (38.2 ± 60.7 μmol/L vs 96.3 ± 143.3 μmol/L; P < 0.0001), and ascitic protein concentration higher (17.9 ± 10.7 g/L vs 14.5 ± 10.9 g/L; P < 0.001) than in inpatients., Conclusion: In asymptomatic cirrhotic outpatients, the incidence of spontaneous bacterial peritonitis is low thus exploratory paracentesis could be avoided in these patients without significant risk.
- Published
- 2013
- Full Text
- View/download PDF
37. Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study.
- Author
-
Nguyen-Khac E, Ollivier I, Aparicio T, Moullart V, Hugentobler A, Lebtahi R, Lobry C, Susini C, Duhamel C, Hommel S, Cadranel JF, Joly JP, Barbare JC, Tramier B, and Dupas JL
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, France, Humans, Immunohistochemistry, Indium Radioisotopes pharmacokinetics, Liver Neoplasms metabolism, Liver Neoplasms pathology, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Radionuclide Imaging methods, Radiopharmaceuticals pharmacokinetics, Receptors, Somatostatin metabolism, Somatostatin analogs & derivatives, Somatostatin pharmacokinetics, Treatment Outcome, Carcinoma, Hepatocellular diagnostic imaging, Liver Neoplasms diagnostic imaging, Receptors, Somatostatin analysis
- Abstract
Background: Somatostatin receptor scintigraphy (SRS) has been reported for receptor (SSTR) screening in advanced hepatocarcinoma (aHC) prior to somatostatin analogue treatment., Aims: To evaluate SSTR screening with SRS in aHC patients., Results: Seventy aHC patients (63 men) aged 65 +/- 11 y were included, with alcohol, viral or other causes cirrhosis in 35 (50%), 23 (33%), 12 (17%) cases respectively. CLIP score was 2.7 +/- 1.7, with more than three nodules in 37 (53%) cases. Largest nodule measured 7.6 +/- 4.5 cm. Median alpha-fetoprotein was 574 UI/mL. SRS was positive in 25/70 (35.7%) livers and 7/17 (41.2%) metastatic sites. Positive SRS patients differed from others for tumor size (9.2 +/- 4 vs. 6.7 +/- 4.6 cm, p = 0.03), prothrombin time (PT) (75.2 +/- 15.2 vs. 61.9 +/- 19%, p = 0.005), albumin (34.1 +/- 5.9 vs. 30.5 +/- 7.2 g/L, p = 0.04) and Child-Pugh (6.7 +/- 1.8 vs. 7.7 +/- 2.3, p = 0.04). After multivariate analysis, only PT was associated with positive SRS (p = 0.028). Immunohistochemistry was positive for SSTR2s in 6/7 tumors (SRS uptake in 5/6 cases)., Methods: SRS was performed prior treatment, with images at 4, 24 and 48 h. For seven tumors, SSTR2 subtype was detected immunohistochemically., Conclusions: In advanced hepatocarcinoma, we report SRS uptake in 35.7% of livers and 41.2% of metastatic sites. SRS value in screening patients for somatostatin analogue treatment remains to be assessed.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.